Thompson Davis & CO. Inc. Acquires 15,700 Shares of Co-Diagnostics, Inc. (NASDAQ:CODX)

Thompson Davis & CO. Inc. boosted its holdings in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) by 37.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 57,200 shares of the company’s stock after purchasing an additional 15,700 shares during the quarter. Thompson Davis & CO. Inc. owned about 0.18% of Co-Diagnostics worth $43,000 at the end of the most recent quarter.

Separately, Jane Street Group LLC bought a new stake in Co-Diagnostics during the 3rd quarter valued at approximately $55,000. Institutional investors own 14.99% of the company’s stock.

Co-Diagnostics Price Performance

NASDAQ:CODX opened at $0.71 on Friday. Co-Diagnostics, Inc. has a 1 year low of $0.65 and a 1 year high of $2.23. The stock’s 50 day simple moving average is $0.75 and its two-hundred day simple moving average is $1.04. The company has a market cap of $22.51 million, a price-to-earnings ratio of -0.51 and a beta of -0.63.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating and set a $1.50 target price on shares of Co-Diagnostics in a research note on Monday, November 11th.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.